Clinical Trials
85 trialsSingle Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia.
National Cancer Institute, Naples
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma
Wondercel Biotech (ShenZhen)
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
Institute of Hematology & Blood Diseases Hospital, China
PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
Peking University First Hospital
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
Suzhou Immunofoco Biotechnology Co., Ltd
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Augusta University
CART-BCMA
Chulalongkorn University
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
SL4903
Institute of Hematology & Blood Diseases Hospital, China
LB2505-0001
Institute of Hematology & Blood Diseases Hospital, China
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Memorial Sloan Kettering Cancer Center
IASO104
Institute of Hematology & Blood Diseases Hospital, China
JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma
Shenzhen Genocury Biotech Co., Ltd.
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
CC-220
Icahn School of Medicine at Mount Sinai
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
The First Affiliated Hospital of Soochow University
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
QLS32015
Institute of Hematology & Blood Diseases Hospital, China
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
64Cu-LLP2A for Imaging Hematologic Malignancies
Washington University School of Medicine
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
Anhui Provincial Hospital
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
Affiliated Hospital of Jiangsu University
A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
Peking University First Hospital
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital of Nanchang University
VitD3 Supplementation in Patients With Multiple Myeloma
Augusta University
A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
Tongji Hospital
Study of CT071 Injection in RRMM or PPCL
Shanghai Changzheng Hospital
To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM
Hrain Biotechnology Co., Ltd.
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
Oncotherapeutics
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Shanghai Cell Therapy Group Co.,Ltd
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Shanghai Changzheng Hospital
64Cu-LLP2A for Imaging Multiple Myeloma
Washington University School of Medicine
Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
Shanghai Changzheng Hospital
An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma
Changzhou No.2 People's Hospital
Study of SYS6020 in BCMA-positive Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
AHCT
Case Comprehensive Cancer Center
To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
Guangdong Second Provincial General Hospital
Study of FasT CAR-T GC012F Injection NDMM Patients
Shanghai Changzheng Hospital
To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects
Nanexa AB
the Safety and Efficacy of SENL103 Autologous T Cell Injection
Hebei Senlang Biotechnology Inc., Ltd.
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
Hrain Biotechnology Co., Ltd.
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
First Affiliated Hospital of Fujian Medical University
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
Rutgers, The State University of New Jersey
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
Rutgers, The State University of New Jersey
89Zr-labeled NY008 PET Imaging in Patients
Affiliated Hospital of Jiangnan University
Clinical Study of the Safety and Efficacy of BCMA CAR-NK
Shenzhen Pregene Biopharma Co., Ltd.
Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)
H. Lee Moffitt Cancer Center and Research Institute